Konruns(SH:603590)2023-04-25 16:00Financial Performance - The company's operating revenue for Q1 2023 was ¥165,105,876.86, representing a year-on-year increase of 5.71%[5]. - The net profit attributable to shareholders decreased by 44.72% to ¥25,668,714.68, primarily due to non-recurring gains from the previous year[5][9]. - The net profit attributable to shareholders after deducting non-recurring gains increased by 229.85% to ¥22,709,397.16, driven by revenue growth from the "Su Ling" product[5][9]. - Basic and diluted earnings per share were both ¥0.16, down 46.67% year-on-year due to the decline in net profit[5][9]. - Operating profit for Q1 2023 was CNY 35,832,956.07, down 34.1% from CNY 54,408,108.46 in Q1 2022[21]. - Net profit for Q1 2023 was CNY 29,864,395.86, a decrease of 40.8% compared to CNY 50,440,303.82 in Q1 2022[21]. - Other comprehensive income after tax for Q1 2023 was CNY 81,339,307.08, compared to a loss of CNY 19,144,953.13 in Q1 2022[21]. - The total comprehensive income for Q1 2023 was CNY 111,203,702.94, significantly higher than CNY 31,295,350.69 in Q1 2022[21]. Cash Flow - The net cash flow from operating activities was ¥14,899,424.58, a decrease of 73.95% compared to the previous year, attributed to increased guarantee payments and reduced receivables[5][9]. - In Q1 2023, the cash inflow from operating activities totaled $213.58 million, a decrease of 9.2% compared to $235.25 million in Q1 2022[24]. - The net cash flow from operating activities was $14.90 million, down 73.9% from $57.19 million in the same period last year[24]. - Cash inflow from investment activities reached $571.83 million, significantly higher than $11.73 million in Q1 2022[25]. - The net cash flow from investment activities was -$117.83 million, slightly worse than -$114.98 million in Q1 2022[25]. - Cash inflow from financing activities amounted to $79.20 million, with a net cash flow of $76.60 million, compared to a net outflow of -$2.21 million in Q1 2022[25]. - The ending cash and cash equivalents balance was $306.65 million, down from $826.39 million at the end of Q1 2022[25]. - The company received $567.33 million from investment recoveries, a significant increase from $11.65 million in the previous year[25]. - The company paid $12.31 million for the purchase of fixed assets, down from $21.71 million in Q1 2022[25]. - The company reported a cash outflow of $2.59 million related to financing activities, compared to $2.21 million in Q1 2022[25]. - The impact of exchange rate changes on cash and cash equivalents was -$347,590.60, compared to -$117,902.72 in the previous year[25]. Assets and Liabilities - Total assets at the end of Q1 2023 were ¥3,597,910,506.27, an increase of 5.05% from the end of the previous year[6]. - The total current assets increased to RMB 1,239,735,492.32, compared to RMB 1,016,711,762.41 in the previous year[18]. - The company's cash and cash equivalents decreased to RMB 309,632,220.59 from RMB 345,245,428.47 year-on-year[17]. - Total liabilities as of Q1 2023 were CNY 296,581,437.26, compared to CNY 234,675,395.76 in Q1 2022, reflecting a 26.4% increase[20]. - The company reported a decrease in accounts payable from RMB 48,474,727.82 to RMB 23,210,002.07 year-on-year[18]. - The company's long-term equity investments slightly decreased to RMB 69,934,534.95 from RMB 70,277,736.99 year-on-year[18]. - The company's intangible assets increased to RMB 861,267,629.07 from RMB 812,748,642.27 year-on-year[18]. - Total equity increased to CNY 3,301,329,069.01 in Q1 2023 from CNY 3,190,125,366.07 in Q1 2022, representing a growth of 3.5%[20]. Research and Development - The company has initiated multiple clinical trials for KC1036, with over 100 advanced solid tumor subjects enrolled[14]. - KC1036 has shown significant clinical efficacy in various cancers, including esophageal, gastric, and lung adenocarcinoma, with a high patient compliance rate[15]. - The company is focused on accelerating the R&D process of KC1036 to bring it to market as soon as possible[15]. - R&D expenses increased to CNY 21,243,679.40 in Q1 2023, up 27% from CNY 16,729,400.94 in Q1 2022[20]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,352[10]. - Shareholders' equity attributable to the parent company increased by 3.66% to ¥3,032,915,967.80[6]. - The weighted average return on equity decreased by 0.74 percentage points to 0.86%[5].